Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on SAR444656 for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia Germany Greece Poland
  • Study on Optimizing Ciclosporin Treatment for Moderate to Severe Atopic Dermatitis in Adults, Adolescents, and Children

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain
  • Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Germany Sweden
  • Study on Dupilumab Step-Down Strategy for Maintaining Remission in Adults and Adolescents with Atopic Dermatitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    France
  • Study on the Long-term Safety and Effectiveness of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Poland
  • Study on Reducing Dupilumab Dose for Patients with Controlled Atopic Eczema

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands
  • Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Czechia France Germany Poland Spain
  • Study on the Long-Term Safety and Effectiveness of Amlitelimab for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    Czechia Denmark France Germany Italy The Netherlands +2
  • Study on the Effects of Vibozilimod for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Estonia Poland
  • Study on Nemolizumab for Children Aged 2-11 with Moderate-to-Severe Atopic Dermatitis Not Controlled by Topical Treatments

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Hungary Poland Spain